GHP Specialty Care AB (GHP) (STO:GHP), a health care provider that operates specialist clinics in a select number of diagnostic areas, reported on Friday result after tax of SEK11.5m, or result per share of SEK0.13, for the second quarter of 2020.
This was a decline over result after tax of SEK12.7m, or result per share of SEK0.17, in Q2 2019.
Sales revenues for the quarter amounted to SEK317.0m, as compared with SEK335.7m in Q2 2019. Organic growth was a negative 8.2%.
According to GHP, revenues decreased in the quarter due to Covid-19 pandemic effects.
As a health care Group, GHP has had to manage the consequences of the COVID-19 pandemic at close quarters. In the Nordic Region it has lent personnel, material and equipment to the public hospitals, at the same time as it had to cancel the appointments of all risk-group patients.
Internationally, GHP adapted to taking care of almost only COVID-19 patients in the UAE, and in Kuwait the hospital is now temporarily a paediatric hospital.
(EUR1.00=SEK10.39)
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline